Barclays CEO To Undergo Treatment For Non-Hodgkin Lymphoma

Barclays Plc (BARC.L,BCS) said on Monday that its Chief Executive Officer C S Venkatakrishnan has informed the Board that he would be undergoing a treatment for Non-Hodgkin Lymphoma.

In a letter, Venkatakrishnan said, "...The doctors have advised that my prognosis is excellent, and my condition is curable with their prescribed regimen. This is likely to last 12 to 16 weeks. During this period, the company will run normally, and I will continue to be actively engaged in managing it. However, I will have to work from home for some periods and not be able to travel."

His treatment is scheduled at Memorial Sloan Kettering Cancer Center in New York.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Health insurer Humana Inc. reported Wednesday a net loss for the fourth quarter that slightly widened from last year, hurt primarily by charges associated with productivity initiatives, despite 6.6 percent revenue growth. Adjusted earnings for the quarter topped analysts' expectations, while quarterly revenues missed it by a whisker. South Plainfield, New Jersey-based Two Rivers Coffee is recalling its peanut butter single serve hot chocolate pods citing an undeclared peanut allergen, the U.S. Food Drug Administration said. The recall involves peanut butter single serve hot chocolate pods distributed as "Brooklyn Bean Peanut Butter Cup Hot Cocoa", "Pingo Peanut Butter Cookie Hot Chocolate" and ... Shares of Novartis AG were losing around 2 percent in the early morning trading in Switzerland after the drug major reported Wednesday sharply lower profit in its fourth quarter with weak sales as well as the absence of prior year's hefty Roche income. Adjusted earnings, however, topped market estimates, while top line missed their view. Further, the company announced higher dividend...
Follow RTT